Informations sur le produit
- (16Alpha)-21-{4-[2,6-Di(Pyrrolidin-1-Yl)Pyrimidin-4-Yl]Piperazin-1-Yl}-16-Methylpregna-1,4,9(11)-Triene-3,20-Dione Methanesulfonate (1:1)
- 21-(4-(2,6-di-1-Pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methylpregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate
- Freedox
- Pregna-1,4,9(11)-triene-3,20-dione, 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methyl-, (16alpha)-, monomethanesulfonate
- Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methyl-, (16α), methanesulfonate (1:1)
- Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methyl-, (16α)-, monomethanesulfonate
- U 74006F
- U74006F
- Unii-19B418Dv39
Tirilazad mesylate is a drug used to treat chronic obstructive pulmonary disease (COPD) or bowel disease. It is a prodrug that is converted in vivo to its active form, tirofiban. Tirilazad mesylate is metabolized by cytochrome P450 enzymes and has been shown to be an experimental model for the study of antioxidant vitamin interactions with drugs. The effects of tirilazad mesylate on rat liver microsomes have been studied using metabolic models. These studies have shown that this drug causes hepatic impairment and decreases energy metabolism. This drug also has a potential for causing toxicity in the central nervous system when given subarachnoidally, which may lead to neuronal death.
Propriétés chimiques
Question d’ordre technique sur : 3D-FT177874 Tirilazad mesylate
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages
